In addition, demonstration and validation of an ALL-like infant AML immunophenotype that includes elevated CD19 expression provides an opportunity for CD19-targetting CAR-T cells, which have shown remarkable success in ALL and other blood disorders [30]. This evidence concerns the gene CD19 and acute myeloid leukemia.